The Latest News from BioAgilytix

A3P Biomedical and BioAgilytix enter partnership for Stockholm3 in the USA

FEATURED STORY

A3P Biomedical and BioAgilytix enter partnership for Stockholm3 in the USA

A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have entered a partnership with the aim of introducing Stockholm3, as...

Cambridge Biomedical is now a part of BioAgilytix

BioAgilytix Announces Acquisition of Boston-Based Clinical Research Organization Cambridge Biomedical

Cambridge Biomedical, a contract research organization based in the Cambridge area of Massachusetts, also specializes in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint into the heart of the world’s major biotech center, and adds further capacity by joining Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility with its GxP laboratories in Durham, North Carolina and Hamburg, Germany.

BioAgilytix Receives Certificate of Registration from CLIA

BioAgilytix Receives Certificate of Registration from CLIA

BioAgilytix has received its Certificate of Registration from the Clinical Laboratory Improvement Amendments (CLIA) program regulated by the Centers for Medicare & Medicaid Services (CMS) for its U.S. facility in Durham, NC. The CLIA certificate confirms that BioAgilytix is now able to perform lab-developed tests in the diagnostic immunology specialty that are deemed “high complexity” and subject to CLIA oversight.

CASE STUDY

Speak To A Scientist






    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.